Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
14.43
-0.36 (-2.43%)
Jun 27, 2025, 4:00 PM - Market closed

Inhibrx Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Net Income
1,7231,688-241.36-115.33
Depreciation & Amortization
2.62.291.191.23
Other Amortization
1.362.074.9-
Loss (Gain) From Sale of Assets
0.010.0100.02
Loss (Gain) on Equity Investments
--1.63-
Stock-Based Compensation
54.5758.5224.8517.79
Other Operating Activities
-1,997-1,9970.131.62
Change in Accounts Receivable
0.560.38-0.540.13
Change in Accounts Payable
13.517.92.11-0.38
Change in Unearned Revenue
---0.17-1.1
Change in Other Net Operating Assets
34.1233.7713.945.21
Operating Cash Flow
-167.25-194.41-193.31-90.81
Capital Expenditures
-1.5-2.6-4.59-0.69
Investing Cash Flow
-1.5-2.6-4.59-0.69
Issuance of Common Stock
32.9571.68202.32-
Other Financing Activities
-0.13--0.3691.5
Financing Cash Flow
132.7971.68201.9691.5
Net Cash Flow
-35.96-125.334.06-
Free Cash Flow
-168.75-197.01-197.9-91.5
Free Cash Flow Margin
-84376.50%-98503.00%-10994.56%-6957.95%
Free Cash Flow Per Share
-10.93-13.15-16.80-
Cash Interest Paid
5.9111.5126.72-
Cash Income Tax Paid
0000
Levered Free Cash Flow
-80.62-118.26-106.38-
Unlevered Free Cash Flow
-76.95-111.89-91.38-
Change in Net Working Capital
-12.675.48-24.17-
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q